胶质母细胞瘤患者血栓与出血并发症的发生率及决定因素
该队列研究纳入两家医院2004至2020年间连续诊断的967例胶质母细胞瘤患者,评估静脉血栓栓塞、动脉血栓栓塞和大出血的累积发生率、预测因素及预后影响。中位随访15个月,1年调整累积发生率静脉血栓栓塞为7.5%、动脉血栓栓塞为4.1%、大出血为12%,静脉血栓栓塞与大出血均与死亡率相关。
要点
- 胶质母细胞瘤患者1年调整累积发生率:静脉血栓栓塞7.5%、动脉血栓栓塞4.1%、大出血12%。
- 随访期间发生的静脉血栓栓塞与大出血相关(调整HR 4.7,95%CI 2.5-9.0)。
- 大出血和静脉血栓栓塞均与死亡率相关(调整HR分别为1.7和1.3)。
核心结论
- 胶质母细胞瘤患者中静脉血栓栓塞和大出血的发生率相当高,且这两种并发症均与较差的预后相关。
- 作者强调需要前瞻性研究来确定这些患者的最佳血栓预防和静脉血栓栓塞治疗策略。
研究设计与样本
- 队列研究,纳入两家医院2004至2020年间连续诊断的967例胶质母细胞瘤患者。
- 随访自组织病理学诊断日期前6个月至诊断后2年,或直至发生感兴趣结局(静脉血栓栓塞、动脉血栓栓塞、大出血)或死亡,取决于分析。
- 采用死亡作为竞争风险估计累积发生率,使用Cox回归识别预测因素和预后影响。
主要发现
- 中位随访15个月(四分位距9.0-22)期间,101例诊断为静脉血栓栓塞,50例诊断为动脉血栓栓塞,126例诊断为大出血。
- 调整后1年累积发生率:静脉血栓栓塞7.5%(95%CI 5.9-9.3),动脉血栓栓塞4.1%(95%CI 3.0-5.6),大出血12%(95%CI 9.6-14)。
- 静脉血栓栓塞的预测因素包括年龄较大、手术类型和体能状态。
- 随访期间发生的静脉血栓栓塞与大出血相关(调整HR 4.7,95%CI 2.5-9.0)。
- 大出血和静脉血栓栓塞与死亡率相关(调整HR分别为1.7,95%CI 1.3-2.1和1.3,95%CI 1.0-1.7)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioblastoma patients are considered to be at high risk of venous thromboembolism (VTE) and major bleeding (MB), although reliable incidence estimates are lacking. Moreover, the risk of arterial thromboembolism (ATE) in these patients is largely unknown. Our aim was to assess the cumulative incidence, predictors, and prognostic impact of VTE, ATE, and MB on subsequent complications and mortality. METHODS: Cohort study of 967 consecutive patients diagnosed with glioblastoma between 2004-2020 in two hospitals. Patients were followed from 6 months before date of histopathological glioblastoma diagnosis up to 2 years after, or until an outcome of interest (VTE, ATE, and MB) or death occurred, depending on the analysis. Cumulative incidences were estimated with death as competing risk. Cox regression was used to identify predictors and the prognostic impact. RESULTS: A total of 101 patients were diagnosed with VTE, 50 with ATE, and 126 with MB during a median follow-up of 15 months (interquartile range 9.0-22). The adjusted 1-year cumulative incidence of VTE was 7.5% (95% confidence interval [CI] 5.9-9.3), of ATE 4.1% (95% CI 3.0-5.6), and of MB 12% (95% CI 9.6-14). Older age, type of surgery, and performance status were predictors of VTE. Incident VTE during follow-up was associated with MB (adjusted HR 4.7, 95% CI 2.5-9.0). MB and VTE were associated with mortality (adjusted HR 1.7, 95% CI 1.3-2.1 and 1.3, 95% CI 1.0-1.7, respectively). CONCLUSION: We found considerable incidences of VTE and MB in glioblastoma patients, with both complications associated with poorer prognosis. Our observations emphasize the need for prospective studies to determine optimal thromboprophylaxis and VTE treatment strategy in these patients.
引用
- Kaptein FHJ, Stals MAM, Kapteijn MY, et al. Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma. J Thromb Haemost. 2022. PMID: 35460331. doi:10.1111/jth.15739
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。